Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver

December 9, 2021

THOUSAND OAKS, Calif., December 9, 2021 — Capsida Biotherapeutics, Inc., an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders, today announced research published in Nature Neuroscience that demonstrated the ability to engineer and select novel capsid variants, with improved enrichment in … Read More

Read More

Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO

December 7, 2021

Longtime industry executive Peter Anastasiou appointed Chief Executive Officer Capsida co-founders Nicholas Flytzanis, Ph.D., promoted to Chief Scientific Officer and Nick Goeden, Ph.D., promoted to Chief Technology Officer Company’s proprietary technology allows for targeted non-invasive gene therapy for the brain and body, while limiting collateral impact on non-targeted areas THOUSAND OAKS, Calif., December 7, 2021 … Read More

Read More

Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference

December 2, 2021

Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, is pleased to announce that co-founder and vice  president of Technology Nick Goeden, PhD,  and Swati Tole, MD MS, will speak at the Gene Therapy for Neurological Disorders … Read More

Read More

Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing

July 22, 2021

New 15,000 square-foot facility in Thousand Oaks will enable industry leading end-to-end gene therapy manufacturing capability THOUSAND OAKS, Calif., July 22, 2021 – Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, today announced the opening of … Read More

Read More

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

June 15, 2021

Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases ZUG, Switzerland, CAMBRIDGE, Mass., and THOUSAND OAKS, Calif. – June 15, 2021 — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing … Read More

Read More

Capsida Appoints Swati Tole, M.D., as Chief Medical Officer

May 12, 2021

Capsida Biotherapeutics Inc., a biotechnology company creating a new class of targeted gene therapies using its next-generation adeno-associated virus (AAV) engineering and cargo development platform, today announced the appointment of Swati Tole, M.D., as the Company’s first chief medical officer.

Read More

Capsida Biotherapeutics Debuts with $140 Million of Capital

April 29, 2021

Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases.

Read More